acetohydroxamic acid ( aha ) , a bacterial urease inhibitor , has been recently approved by the united states food and drug administration as a potential drug for the successful treatment of patients with infection induced staghorn renal calculi .
C0050451
acetohydroxamic acid
C2266864
urease inhibitor